Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is headquartered in Los Angeles, California and currently employs 16 full-time employees. The company went IPO on 2020-12-17. The firm is engaged in the development of androgen-based medicines. The firm is focused on the commercialization of JATENZO, which is an oral testosterone replacement or testosterone replacement therapy (TRT). JATENZO is a created by the linkage of T with the fatty acid undecanoic acid to form testosterone undecanoate. JATENZO is developed for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. The company also focuses on the signs and symptoms associated with hypogonadism such as psychosexual symptoms, body mass index, fat mass and bone mineral density. The Company’s subsidiary is Clarus Therapeutics, Inc.

Industry: Biological Products, (No Diagnostic Substances) Peers: Kaya Holdings Inc Baudax Bio, Inc. Bespoke Extracts Inc Gelstat Corp Innovation1 Biotech Inc. Johnson & Johnson NEUROPATHIX, INC.